HUMA Stock Price, Humacyte, Inc. Quote, Chart

Market Summary

USD3.83-0.10

Market Closed

-2.54%

HUMA Stock Price

View Fullscreen

HUMA RSI Chart

HUMA Valuation

Market Cap

468.0M

Price/Earnings (Trailing)

-4.22

Price/Sales (Trailing)

206.02

Price/Free Cashflow

-6.19

HUMA Price/Sales (Trailing)

HUMA Profitability

Return on Equity

-817.78%

Return on Assets

-86.39%

Free Cashflow Yield

-16.15%

HUMA Fundamentals

HUMA Revenue

Revenue (TTM)

1.6M

HUMA Earnings

Earnings (TTM)

-110.8M

Earnings Growth (Yr)

-574.89%

Earnings Growth (Qtr)

3.42%

Breaking Down HUMA Revenue

Last 7 days

28.4%

Last 30 days

18.7%

Last 90 days

37.4%

Trailing 12 Months

15.6%

How does HUMA drawdown profile look like?

HUMA Financial Health

Current Ratio

4.52

HUMA Investor Care

Shares Dilution (1Y)

15.25%

Diluted EPS (TTM)

-1.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	1.3M	2.0M	1.7M	1.6M
2021	3.7M	2.9M	2.1M	1.3M
2020	0	0	5.4M	4.5M
2019	0	0	0	6.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Humacyte, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 21, 2023	wallace max n.	acquired	7,811	1.19	6,564	-
Oct 10, 2023	niklason laura e	acquired	136,160	1.19	114,420	president, ceo and director
Oct 10, 2023	dougan brady w	acquired	136,160	1.19	114,420	-
Sep 14, 2023	niklason laura e	sold	-5,560,000	2.78	-2,000,000	president, ceo and director
Sep 14, 2023	dougan brady w	sold	-5,560,000	2.78	-2,000,000	-
Aug 21, 2023	ayabudge llc	sold	-2,042,280	3.39	-602,443	-
Aug 21, 2023	dougan brady w	sold	-2,042,280	3.39	-602,443	-
Aug 21, 2023	niklason laura e	sold	-2,042,280	3.39	-602,443	president, ceo and director
Aug 18, 2023	niklason laura e	sold	-2,238,320	3.57	-626,979	president, ceo and director
Aug 18, 2023	ayabudge llc	sold	-2,238,320	3.57	-626,979	-

Which funds bought or sold HUMA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	United Asset Strategies, Inc.	added	0.14	60,686	689,201	0.07%
Apr 23, 2024	SEVEN GRAND MANAGERS, LLC	new	-	155,500	155,500	0.08%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.87	-17,000	6,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-3,143	99,196	-%
Apr 22, 2024	Byrne Asset Management LLC	added	50.00	3,370	9,330	0.01%
Apr 16, 2024	Powell Investment Advisors, LLC	sold off	-100	-59,640	-	-%
Apr 05, 2024	GAMMA Investing LLC	unchanged	-	-24.00	348	-%
Apr 05, 2024	CWM, LLC	sold off	-100	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	3.45	24,502	8,870,080	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	51.97	183,697	572,010	-%

Are Funds Buying or Selling HUMA?

Are funds buying HUMA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HUMA

No. of Funds

Unveiling Humacyte, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 08, 2024	niklason laura e	8.4%	10,153,195	SC 13D/A
Mar 07, 2024	fresenius medical care holdings inc /ny/	15.4%	18,312,735	SC 13D/A
Dec 01, 2023	fresenius medical care holdings inc /ny/	-	0	SC 13D/A
Sep 15, 2023	niklason laura e	9.5%	10,050,822	SC 13D/A
Aug 22, 2023	niklason laura e	11.1%	11,612,809	SC 13D/A
Jun 15, 2023	niklason laura e	13.2%	13,911,388	SC 13D/A
May 26, 2023	niklason laura e	17.9%	18,786,211	SC 13D/A
Sep 19, 2022	niklason laura e	21.3%	22,336,411	SC 13D/A
Feb 14, 2022	glazer capital, llc	0.0%	0	SC 13G/A
Feb 09, 2022	parian global management lp	0%	0	SC 13G/A

Recent SEC filings of Humacyte, Inc.

View All Filings

Date Filed	Form Type	Document
Mar 28, 2024	S-8	Employee Benefits Plan
Mar 28, 2024	10-K	Annual Report
Mar 22, 2024	8-K	Current Report
Mar 08, 2024	SC 13D/A	13D - Major Acquisition
Mar 07, 2024	SC 13D/A	13D - Major Acquisition
Mar 04, 2024	8-K	Current Report
Mar 01, 2024	424B5	Prospectus Filed
Feb 29, 2024	8-K	Current Report
Feb 29, 2024	424B5	Prospectus Filed
Feb 09, 2024	8-K	Current Report

Peers (Alternatives to Humacyte, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Humacyte, Inc. News

Latest updates

Humacyte, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)												(In Thousands)
Description	(%) Q/Q	2023Q4	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Revenue	-	-	-	31.00	1,301	233	177	241	690	-	-	-	-
Operating Expenses	25.9%	26,182	20,790	23,525	19,832	21,996	21,804	20,784	19,959	19,924	15,796	18,127	-
S&GA Expenses	2.9%	6,002	5,833	6,188	5,180	5,682	5,554	5,398	5,391	4,787	2,597	3,435	-
R&D Expenses	34.9%	20,180	14,957	17,337	14,652	16,314	16,250	15,386	14,568	15,137	13,199	14,692	-
Interest Expenses	5.4%	1,727	1,639	1,641	1,488	1,432	1,396	1,204	1,215	533	541	549	-
Net Income	-574.9%	-25,106	-3,720	-25,281	36,868	-19,832	42,585	-31,563	-17,198	-20,301	-16,212	-17,760	-
Net Income Margin	-825.8%	-70.78*	-7.65*	23.45*	20.58*	-19.07*	-20.96*	-40.92*	-24.61*	-18.56*	-14.63*	-15.92*	-
Free Cashflow	2.3%	-19,150	-19,610	-17,045	-16,703	-18,819	-21,503	-30,602	-14,786	-14,529	-7,724	-34.05	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-14.2%	128	149	168	183	204	226	246	264	287	303	101	101	107	101	169
Current Assets	-19.0%	83.00	103	121	134	154	175	193	209	229	244	0.00	1.00	41.00	1.00	95.00
Cash Equivalents	-19.5%	80.00	100	115	130	150	164	181	198	218	240	29.00	45.00	40.00	55.00	94.00
Net PPE	-3.8%	27.00	28.00	29.00	30.00	30.00	31.00	32.00	34.00	35.00	36.00	38.00	-	41.00	-	47.00
Liabilities	2.0%	115	112	107	101	87.00	108	104	161	164	228	17.00	17.00	36.00	36.00	36.00
Current Liabilities	21.8%	18.00	15.00	11.00	24.00	20.00	18.00	11.00	11.00	11.00	21.00	0.00	0.00	11.00	0.00	11.00
Shareholder's Equity	-63.4%	14.00	37.00	61.00	82.00	117	119	142	104	122	76.00	5.00	5.00	5.00	5.00	-
Retained Earnings	-4.9%	-537	-512	-486	-463	-426	-422	-397	-434	-414	-457	-7.73	-8.02	-388	-0.04	-321
Additional Paid-In Capital	0.3%	551	549	547	545	543	541	540	538	537	533	13.00	13.00	38.00	5.00	33.00
Shares Outstanding	0.2%	104	103	103	103	103	103	103	103	103	19.00	6.00	6.00	6.00	-	-
Float	-	-	-	178	-	-	-	166	-	-	-	102	-	102	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	-45.5%	-19,000	-13,056	-22,603	-18,641	-18,959	-16,804	-16,566	-18,800	-21,490	-30,500	-14,657	-14,543	-7,727	-18.05	-	-
Share Based Compensation	-20.7%	1,406	1,772	1,841	1,809	1,670	1,476	1,491	1,547	2,811	1,877	2,930	2,528	1,228	1,170	-	-
Cashflow From Investing	69.6%	-150	-493	1,622	-1,152	5,212	-211	-134	-22.00	-8,045	-83.00	-63.00	-29.00	-6.50	-100,000	-	-
Cashflow From Financing	56.2%	-335	-764	6,015	-409	-212	-289	-484	-461	6,546	242,082	-916	19,271	-160	101,334	-	-

HUMA Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Grant revenue	$ 0	$ 1,565
Operating expenses:
Research and development	76,550	63,260
General and administrative	23,497	22,883
Total operating expenses	100,047	86,143
Loss from operations	(100,047)	(84,578)
Other income (expense), net
Interest income	5,467	2,629
Change in fair value of Contingent Earnout Liability	(10,023)	75,767
Employee retention credit	3,107	0
Loss on extinguishment of debt	(2,421)	0
Interest expense	(6,599)	(6,200)
Change in fair value of derivative liabilities	(260)	417
Total other income (expense), net	(10,729)	72,613
Net loss	(110,776)	(11,965)
Comprehensive loss	$ (110,776)	$ (11,965)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (1.07)	$ (0.12)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (1.07)	$ (0.12)
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic (in shares)	103,420,238	103,051,366
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in shares)	103,420,238	103,051,366

HUMA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 80,448	$ 149,772
Prepaid expenses and other current assets	2,830	2,298
Short-term investments	0	2,107
Accounts receivable	0	31
Total current assets	83,278	154,208
Property and equipment, net	26,791	30,039
Finance lease right-of-use assets, net	17,313	19,373
Other long-term assets	841	682
Total assets	128,223	204,302
Current liabilities
Accounts payable	6,490	1,595
Accrued expenses	9,340	7,108
Finance lease obligation, current portion	2,560	2,256
Operating lease obligation, current portion	53	50
SVB loan payable, current portion	0	8,571
Total current liabilities	18,443	19,580
Revenue interest liability	38,600	0
Contingent Earnout Liability	37,916	27,893
Finance lease obligation, net of current portion	16,293	18,853
Contingent derivative liability	2,636	0
Other long-term liabilities	789	712
SVB loan payable, net of current portion	0	20,336
Total liabilities	114,677	87,374
Commitments and contingencies (Note 13)
Stockholders’ equity
Preferred stock, $0.0001 par value; 20,000,000 shares designated as of December 31, 2023 and 2022; 0 shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.0001 par value; 250,000,000 shares authorized as of December 31, 2023 and 2022; 103,673,728 and 103,229,013 shares issued and outstanding as of December 31, 2023 and 2022, respectively	10	10
Additional paid-in capital	550,850	543,456
Accumulated deficit	(537,314)	(426,538)
Total stockholders’ equity	13,546	116,928
Total liabilities and stockholders’ equity	$ 128,223	$ 204,302

About Humacyte, Inc.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

CEO	Dr. Laura E. Niklason M.D., Ph.D.
WEBSITE	humacyte.com
INDUSTRY	Biotechnology
EMPLOYEES	164

Humacyte, Inc. Frequently Asked Questions

What is the ticker symbol for Humacyte, Inc.? What does HUMA stand for in stocks?

HUMA is the stock ticker symbol of Humacyte, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Humacyte, Inc. (HUMA)?

As of Tue Apr 23 2024, market cap of Humacyte, Inc. is 468 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HUMA stock?

You can check HUMA's fair value in chart for subscribers.

What is the fair value of HUMA stock?

You can check HUMA's fair value in chart for subscribers. The fair value of Humacyte, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Humacyte, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HUMA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Humacyte, Inc. a good stock to buy?

The fair value guage provides a quick view whether HUMA is over valued or under valued. Whether Humacyte, Inc. is cheap or expensive depends on the assumptions which impact Humacyte, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HUMA.

What is Humacyte, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, HUMA's PE ratio (Price to Earnings) is -4.22 and Price to Sales (PS) ratio is 206.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HUMA PE ratio will change depending on the future growth rate expectations of investors.